BALCAO · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP
Harvard Apparatus Regenerative Technology, Inc. HRGN
14 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$704,000
▲ 63.7% vs FY2024
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-321.1%
Net margin · FY25
-975.7%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 704,000.00
Revenue, FY2025 · full 14-year series below
Revenue
Net income
The company lost 976 cents on every revenue dollar this year.
Per share
—
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-321.1%
Return on equity, FY2025
ROE
Operating margin-982.2%
Net margin-975.7%
Return on assets-193.0%
Each USD of equity lost 321 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+19.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.02B
Shares outstanding, FY2025
Change, 5 years+87.3%
Change, 10 years—
The share count grew 87% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 2.7M
total assets, end of FY2025
Total assetsUSD 2.7M
EquityUSD 1.1M
CashUSD 1.4M
Current ratio1.19×
Equity funds 39% of total assets.
History
14 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
Revenue $B
0.0
0.0
0.0
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
·
·
·
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
·
·
−0.67
−0.55
−0.79
−0.55
−1.21
−1.69
−6.63
−14.49
−1.05
−1.41
−1.14
−0.87
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−321.1
−317.7
·
·
·
−439.5
−544.6
−279.2
−458.6
−229.8
−158.2
−105.0
−120.8
−24863.0
Shares out B
0.02
0.02
0.01
0.01
0.01
0.01
0.01
0.01
0.00
0.00
0.01
0.01
0.01
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
48 of 48
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed